This report was first published by Endpoints News. To see the original version, click here
Sanofi CEO Paul Hudson bet big on immunology. When Belén Garijo takes over as CEO next week, she will have to decide whether to continue that wager.
The direction Garijo elects to pursue will likely have ramifications not just for Sanofi’s R&D future, but for the company’s identity. Under Hudson, Sanofi went all-in on immunology, trying to tackle a wide range of diseases, from eczema and asthma to multiple sclerosis and rare neuroinflammatory conditions.
您已阅读10%（547字），剩余90%（4673字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。